6PGD-IN-S3

CAS No. 5539-66-2

6PGD-IN-S3( 6PGD Inhibitor S3 | S3 | Danthron methyl derivative )

Catalog No. M27840 CAS No. 5539-66-2

6PGD-IN-S3 is an inhibitor of 6-phosphogluconate dehydrogenase (6PGD).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 272 In Stock
10MG 402 In Stock
25MG 664 In Stock
50MG 888 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    6PGD-IN-S3
  • Note
    Research use only, not for human use.
  • Brief Description
    6PGD-IN-S3 is an inhibitor of 6-phosphogluconate dehydrogenase (6PGD).
  • Description
    6PGD-IN-S3 is an inhibitor of 6-phosphogluconate dehydrogenase (6PGD).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    6PGD Inhibitor S3 | S3 | Danthron methyl derivative
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Dehydrogenase
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    5539-66-2
  • Formula Weight
    254.241
  • Molecular Formula
    C15H10O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COc1cccc2C(=O)c3cccc(O)c3C(=O)c12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.H Kikukawa, et al. Production of cis-11-eicosenoic acid by Mortierella fungi. J Appl Microbiol. 2015 Mar;118(3):641-7.
molnova catalog
related products
  • G-749

    G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.

  • Enoxolone

    Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption.

  • BI-4916

    BI-4916 is a selective phosphoglycerate dehydrogenase (PHGDH) inhibitor that inhibits SSP and reduces the migration of cancer cells.BI-4916 can be used in the study of cancer and metabolic diseases.